Overview

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Status:
Terminated

Trial end date:
2017-07-24

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies